Results 21 to 30 of about 14,967 (152)

Novel cancer-fighting role of ticagrelor inhibits GTSE1-induced EMT by regulating PI3K/Akt/NF-κB signaling pathway in malignant glioma

Heliyon
Background: Glioma is the most common malignant brain tumor of the central nervous system. Despite of the improvement of therapeutic strategy, the prognosis of malignant glioma patients underwent by STUPP strategy is still unexpected.
Enzhou Lu, Boxian Zhao, Chao Yuan, Yanchao Liang, Xiaoxiong Wang, Guang Yang   +5 more
doaj   +1 more source

Appropriateness of Ticagrelor Use at Initiation: A Population-Based Cohort Study

Journal of Pharmacy & Pharmaceutical Sciences, 2018
Purpose. Ticagrelor is recommended following an acute coronary syndrome if used appropriately. Its use has not yet been well described in the context of ambulatory clinical practice.
Jean-Pierre Gregoire, Paul Poirier, Norma Pérez, Éric Demers, Jocelyne Moisan   +4 more
doaj   +1 more source

Clinical implication of ticagrelor monotherapy in patients with small vessel coronary artery disease: results from the TICO randomized trial

Frontiers in Cardiovascular Medicine, 2023
BackgroundThe aim of this study was to evaluate the efficacy and safety of ticagrelor monotherapy in patients with small vessel disease compared with ticagrelor-based DAPT within the Ticagrelor Monotherapy after 3 Months in the Patients Treated with New ...
Jae Young Cho, Donghyeon Joo, Kyeong Ho Yun, Byeong-Keuk Kim, Myeong-Ki Hong, Yangsoo Jang, Seok Kyu Oh   +6 more
doaj   +1 more source

The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population [PDF]

PeerJ
Background Ticagrelor is a novel oral antiplatelet agent which can selectively inhibit P2Y12 receptor. Bleeding and dyspnea are common adverse reactions of ticagrelor in clinic.
Xiaoxia Hu, Peng Wang, Dali Zeng, Guo-xin Hu   +3 more
doaj   +2 more sources

Ticagrelor Does Not Inhibit Adenosine Transport at Relevant Concentrations: A Randomized Cross-Over Study in Healthy Subjects In Vivo. [PDF]

PLoS ONE, 2015
In patients with myocardial infarction, ticagrelor reduces cardiovascular and sepsis-related mortality, and can cause dyspnea. It is suggested that this is caused by adenosine receptor stimulation, because in preclinical studies, ticagrelor blocks the ...
T N A van den Berg, S El Messaoudi, G A Rongen, P H H van den Broek, A Bilos, A R T Donders, M E Gomes, N P Riksen   +7 more
doaj   +1 more source

Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes

Journal of Cardiothoracic Surgery, 2021
Background Management of patients treated with Ticagrelor is challenging, as stopping Ticagrelor prior to coronary bypass graft surgery (CABG) may increase the risk of acute stent thrombosis.
Sammer Diab, Mattan Arazi, Leonid Sternik, Ehud Raanani, Erez Kachel, Liza Grosman-Rimon, Amjad Shalabi, Offer Amir, Shemy Carasso   +8 more
doaj   +1 more source

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

British Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale, Clare Guilding, Jennifer Koenig, Michael Okorie, Reecha Sofat, Simon Maxwell   +5 more
wiley   +1 more source

Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats

Pharmaceutics, 2019
Tadalafil is a cytochrome P450 (CYP) 3A4 substrate. Because there are few data on drug-drug interactions, it is advisable to take sufficient consideration when co-administering tadalafil with CYP3A4 inducers or inhibitors.
Young-Guk Na, Jin-Ju Byeon, Hyun Wook Huh, Min-Ki Kim, Young G. Shin, Hong-Ki Lee, Cheong-Weon Cho   +6 more
doaj   +1 more source

Dual Artery Compression for Patent Hemostasis and Prevention of Radial Artery Occlusion: The Quebec Terry2 Registry

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Radial artery occlusion (RAO) is a common complication following transradial artery access (TRA). Patent hemostasis is recommended to reduce RAO. Prophylactic ulnar artery compression is a technique to increase the rate of patent hemostasis.
Tomas A. Cieza, Francis Bonnenfant, Jimmy MacHaalany, Paola Ulacia‐Flores, Safia Ouarrak, Andres Ruhl, Erika Pomerleau, Joany Lapierre, Olivier F. Bertrand   +8 more
wiley   +1 more source

Does the level of myocardial injury differ in primary angioplasty patients loaded first with clopidogrel and the ones with ticagrelor?

Anatolian Journal of Cardiology, 2020
Objective: In daily clinical practice, we encounter ST segment elevation myocardial infarction (STEMI) patients loaded with clopidogrel upon admission to primary angioplasty.
Nil Ozyuncu, Hüseyin Göksülük, Turkan Seda Tan, Kerim Esenboga, Yusuf Atmaca, Çetin Erol   +5 more
doaj   +1 more source